Tempest Therapeutics
TPST-4003 combines CD7-targeted mRNA/LNP delivery with a CD19/BCMA CAR; first IIT dosing was projected for Q4 2026, not verified as completed. Tempest separately obtained an option to license Senlang’s clinical lentiviral platform. TPST-2003 clinical results concern ex vivo CAR-T.
Corporate information
- Company entity
- Tempest Therapeutics
- Headquarters / principal office
- Brisbane, California, USAOffice location disclosed on the corporate website; a sole legal or global headquarters is not inferred. ↗
- Founded
- 2011 (incorporation) ↗
- Ownership / capital status
- Publicly tradedNasdaq-listed: TPST ↗
- Official corporate reference
- https://www.tempesttx.com/ ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
TPST-4003 combines CD7-targeted mRNA/LNP delivery with a CD19/BCMA CAR; first IIT dosing was projected for Q4 2026, not verified as completed. Tempest separately obtained an option to license Senlang’s clinical lentiviral platform. TPST-2003 clinical results concern ex vivo CAR-T.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Tempest Therapeutics — primary program / ownership disclosure
- Tempest Therapeutics — supporting primary disclosure
- Official corporate website audit
- Primary corporate profile / legal-entity disclosure